Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Keywords
- Tenofovir Disoproxil Fumarate
- Fact Sheet
- Total Lymphocyte Count
- Serum Amylase Level
- Start Tuberculosis Treatment
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
ADRAC, 2003, Interactions with grape fruit juice – amendment. Austr Adv React Bull 22(2): 4.
Clinton W.J., 2003, Turning the tides on the AIDS pandemic. N Engl J Med 348: 1800–1802.
Collier A.C., Coombs R.W., et al., 1996, Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 334: 1011–1017.
Connor E.M., Sperling R.S., Gelber R., et al., 1994, Reduction of maternal-infant transmission of human immuno-deficiency virus type 1 with zidovudine treatment. N Engl J Med 331: 1173–1180.
Coombs R.W., Speck C.E., Hughes J.P., et al., 1998, Association between culturable human immuno-deficiency virus type-I (HIV-1) in semen and HIV RNA levels in semen and blood – evidence for compartmentalization of HIV-1 in semen and blood. J Inf Dis 177: 320–330.
Durant J., Clevenbergh P., Halfon P., et al., 1999, Drug resistance genotyping in HIV-1 therapy – the VIRADAPT randomized control trial. Lancet 353: 2195–2199.
Fischl M.A., Richman D.D., Griece M.H., et al., 1987, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 317: 185–191.
Food and Drug Administration (FDA), 2006, FDA News. July 12. http://www.fda.gov/cder/drug/infopage/atripla/.
Furtado M.R., Callaway D.S., Phair J.P., et al., 1999, Persistence of HIV transcription in peripheral-blood mononuclear cells in patients receiving potent anti-retroviral therapy. N Engl J Med 340: 1614–1622.
Harries A., Maher D., and Graham S., 2004, TB/HIV – a clinical manual. 2nd edn. Geneva: WHO. pp. 137–154.
Harrigan P.R., Whaley M., and Montaner J.S., 1999, Rate of HIV-1 RNA rebound upon stopping anti-retroviral therapy. AIDS 13: F 59–F 62.
John T.J., 2001, AIDS control and retrovirus drugs. Economic and Political Weekly July 7, pp 2489–2490.
John T.J., 2004, HAART in India: heartening prospects and disheartening problems (Editorial). Indian J Med Res 119: iii–vi.
Kelly M., 2002, The state of play: HIV treatment. HIV Australia 1: 13–15.
Kreudhutha N., et al., 2005, Experience of a community-based antiretroviral Buyers' Club in Thailand. Essent Drugs Monit 34: 10–11.
Land S., McGavin C., Lucas R., et al., 1992, Incidence of ZDV-resistant human immunodeficiency virus isolated from patients before, during and after therapy. J Infect Dis 166: 1139–1142.
Lewin S.R., Crowe S., Chambers D.E., and Cooper D.A., 1997, Antiretroviral therapies for HIV. In: Managing HIV (G.J. Stewart, ed.). North Sydney: Australasian Medical Publishing, pp 45–54.
Liu H., Golin C.E., Miller L.G., 2001, A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Int Med 134(10): 968–977.
Masquelier B., et al., 2005, Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms data from seroconverters in the CASCADE collaboration from 1987 to 2003. J AIDS 40: 505–511.
Mulder J.W., Cooper D.A., Mathiesen L., et al., 1994, Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomised, double-blind placebo-controlled study. AIDS 8: 313–321.
NACO. National guidelines for clinical management of HIV/AIDS. New Delhi: Government of India.
National Institute of Allergy and Infectious Diseases (NIAID), 2005, HIV infection and AIDS: an overview, NIAID fact sheet. Bethesda: National Institutes of Health, March. http://www.niaid.nih.gov/.
New Mexico AIDS Education and Training Center, 2005, Fact Sheet 430. Non-nucleoside reverse transcriptase inhibitors in development. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 19 November.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 157. Microbicides. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 9 March.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 401. Taking current anti-retroviral drugs. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 14 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 402. Anti-viral drug names. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 25 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 408. Salvage therapy. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 10 May.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 410. Nucleoside analog reverse transcriptase inhibitors. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 16 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 440. Protease inhibitors in development. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 30 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 449. Tipranavir. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 8 July.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 450. Darunavir. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 25 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 460. Attachment and fusion inhibitors in development. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 14 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 461. Enfuvirtide. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 9 March.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 470. Other anti-retroviral drugs in development. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 14 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 479. Hydroxyurea. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 20 July.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 480. Immune Therapies in development. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 30 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 481. Immune Restoration. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 20 June.
New Mexico AIDS Education and Training Center, 2006, Fact Sheet 724. DHEA. University of New Mexico Health Sciences Center. http://www.aidsinfonet.org. Revised 1 May.
Nwokike J.L., 2005, Baseline data and predictors of adherence in patients on anti-retroviral therapy in Maun General Hospital, Botswana. Essent Drugs Monit 34: 12–13.
Palella F.J. Jr., Deloria-Knoll M., Chmiel J.S., et al., 2003, Survival benefit of initiating anti-retroviral therapy in HIV-infected persons in different CD4 + cell strata. Ann Intern Med 138(8): 620–626.
Parienti J.J., Verdon R., Bazin C., 2001, The pills identification test: a tool to assess adherence to antiretroviral therapy. JAMA 285(4): 412.
Potter S.J., Chew C.B., Steain M., et al., 2004, Obstacles to successful anti-retroviral treatment of HIV-1 infections: problems and perspectives. Indian J Med Res 119: 217–237.
Sepkowitz K.A., 2006, One disease, two epidemics – AIDS at 25. N Engl J Med 354: 2411–2414.
WHO, 2003a, Scaling up anti-retroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva: WHO; 2003 Revision.
WHO, 2003b, South Africa – a novel approach to improving adherence to TB treatment. Essent Drugs Monit 33: 8.
Whyte S.R., et al., 2005, Accessing retroviral drugs: dilemmas for families and health workers. Essent Drugs Monit 34: 14–15.
Wig N., 2002, Anti-retroviral therapy – are we aware of adverse effects? JAPI 50: 1163–1171.
Wong J.K., Hezareh M., Gunthard H.F., et al., 1997, Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291–1295.
Zhang H., Dornadula G., Beumount M., et al., 1998, Human immuno-deficiency virus type-1 in the semen of men receiving highly active anti-retroviral therapy. N Engl J Med 339: 1803–1809.
Rights and permissions
Copyright information
© 2007 Springer
About this chapter
Cite this chapter
(2007). Antiretroviral Therapy. In: HIV and AIDS: Basic Elements and Priorities. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5789-2_16
Download citation
DOI: https://doi.org/10.1007/978-1-4020-5789-2_16
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-5788-5
Online ISBN: 978-1-4020-5789-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)